Suchergebnisse - "Huang, Xiao-Yong"

PubPharm (97)

1

Correction : Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

enthalten in: Molecular cancer | 2024

von Huang, X. | Zhang, P. | Wei, C. | +9

ErratumFor: Mol Cancer. 2020 May 19;19(1):92. - PMID 32430013

2

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

enthalten in: Nature communications | 2024

von Lu, J. | Wu, L. | Sun, Y. | +27

3

Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy

enthalten in: Cancer letters | 2023

von Dong, Z. | Cai, J. | Shi, G. | +8

4

Corrigendum to : "PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176

enthalten in: Journal of hepatology | 2023

von Wei, C. | Zhu, M. | Zhang, P. | +17

ErratumFor: J Hepatol. 2022 Jul;77(1):163-176. - PMID 35219791

5

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma : a single-center, single-arm, phase 2 study

enthalten in: Signal transduction and targeted therapy | 2023

von Shi, G. | Huang, X. | Wu, D. | +20

6

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion

enthalten in: Hepatology international | 2023

von Meng, X. | Lu, J. | Zeng, H. | +19

7

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements : A phase II study

enthalten in: Cancer medicine | 2023

von Shi, G. | Huang, X. | Wen, T. | +27

8

Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis

enthalten in: Cell death & disease | 2023

von Guo, X. | Huang, X. | Yang, X. | +15

9

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements : A phase II study

enthalten in: Cancer Medicine | 2023

von Shi, G. | Huang, X. | Wen, T. | +27

10

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion

enthalten in: Hepatology international | 2022

von Meng, X. | Lu, J. | Zeng, H. | +19

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]